Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$1.17 0.02 (1.74%)
2/9/2010 4:00 PM

Javelin Pharmaceuticals, Inc. (JAV)

CAPS Rating:
*****

The Company is engaged in the research, development and commercialization of innovative treatments for the relief of moderate to severe pain.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

JAV doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

209 Outperforms
10 Underperforms
 

All-Stars

64 Outperforms
3 Underperforms
 

Wall Street

7 Outperforms
0 Underperforms
 

Members bullish on JAV are also bullish on:

Members bearish on JAV are also bearish on:

Ticker Tags

Healthcare (711), Pharmaceuticals (149), Micro Cap (4701), Defensive (1457)
Suggest a tag

Javelin Pharmaceuticals, Inc. At A Glance

Current Price: $1.17
Last Trade Time: 2/9/2010 4:00 PM
Open: $1.16
Previous Close: $1.15
Daily Range: $1.16 - $1.21
52-Week Range: $1.01 - $2.28
Volume: 369,275
Market Cap: $74.72M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

JAV VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

4

Javelin Pharmaceuticals, Inc. (JAV)

Avatar Pennyperson (83.50) Submitted: 9/21/09 4:37 PM

Company is in a great position to be acquired due to its relatively low market cap compared to its large cap peers. With low cash position, and three late-staged drugs- this equals to million(s) of dollars in revenue potential.
The pain management drugs have the attention of the military. They did ...More

Replies: 2 | Reply | Permalink

Top Bear Pitch

Recs

1

Javelin Pharmaceuticals, Inc. (JAV)

Avatar cut2qr (32.33) Submitted: 3/29/07 1:58 AM

Three drugs for post operative pain relief in phase 3 trials due to report next 3mo with one Wall Street pro saying a "transforming event" is around the corner. Sound's good BUT- 1st candidate is an injectable NSAID (Dyloject) that has been availble orally for 20 yrs, will compete with Toradol the p...More

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 38 :   1 2 3 4 5 Next »

Show Pitch Replies

Recs

1

 (JAV)

Avatar sprint17 (79.78) Submitted: 1/20/10 4:15 AM : Outperform Start Price: $1.84 JAV Score: -36.07

Although the buyout by Myriad is being hampered by a lawsuit by shareholders, the price of JAV should rebound to at LEAST $1.49, as that is the approximate price the Myriad is transferring their own shares at. If the lawsuit turns out in favor of the plaintiffs, then it could perhaps go higher. I'm not giving up on this one yet.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (JAV)

Avatar bg11235 (96.10) Submitted: 10/19/09 12:53 PM : Outperform Start Price: $1.66 JAV Score: -27.07

One more on BravoBevo's coattails.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (JAV)

Avatar expatriot08 (84.98) Submitted: 10/13/09 12:24 PM : Outperform Start Price: $1.72 JAV Score: -31.81

Low market Cap pharma. Getting in now and hoping for good news in October conference call. Fingers crossed for a partnership and not not shares dilution.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (JAV)

Avatar 08PortfolioModel (< 20) Submitted: 10/07/09 10:40 PM : Outperform Start Price: $1.65 JAV Score: -27.53

Current 1.76, Oct 7 09. Limit 1.66

Report this Post Replies: 0 | Reply | Permalink

Recs

4

 (JAV)

Avatar Pennyperson (83.50) Submitted: 9/21/09 4:37 PM : Outperform Start Price: $2.04 JAV Score: -42.78

Company is in a great position to be acquired due to its relatively low market cap compared to its large cap peers. With low cash position, and three late-staged drugs- this equals to million(s) of dollars in revenue potential.
The pain management drugs have the attention of the military. They did have a recent sit back on the mixed Phase III data for its Ereska drug candidate to treat post-operative pain. However, they will reevaluate and continue to test it further.
JAV did beat earnings estimates in the last reported quarter and Mr. Zack is ranking this a Strong Buy with Reuters ranking it Outperform.
For around $2, it appears to be an opportunity to double your investment by mid 2010. However, with an acquisition - you could see it fly to $5 or $6 or an extreme $7

Report this Post Replies: 2 | Reply | Permalink

Results 1 - 5 of 38 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 7 of 7  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackStanfordRes 85.54 09/25/08 Outperform NS $2.80-58.21%-7.95%-50.26
TrackCanaccord 86.15 01/31/08 Outperform NS $3.67-68.12%-17.65%-50.47
TrackFortisBank 83.59 07/23/07 Outperform NS $5.23-77.63%-26.82%-50.81
TrackJPMorgan 84.76 05/29/07 Outperform NS $7.15-83.64%-25.39%-58.24
TrackPacificGrow 89.01 05/22/07 Outperform NS $6.65-82.41%-25.70%-56.71
TrackPZK < 20 03/15/07 Outperform NS $7.15-83.64%-18.61%-65.03
TrackRodmanRen < 20 01/31/07 Outperform NS $5.05-76.83%-20.21%-56.62

Results 1 - 7 of 7  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD02 406ms